Shu-Ming Kuo

ORCID: 0000-0002-4437-689X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Influenza Virus Research Studies
  • Respiratory viral infections research
  • SARS-CoV-2 and COVID-19 Research
  • Viral gastroenteritis research and epidemiology
  • Animal Virus Infections Studies
  • Monoclonal and Polyclonal Antibodies Research
  • Microbial Metabolic Engineering and Bioproduction
  • GABA and Rice Research
  • Animal Disease Management and Epidemiology
  • Bacteriophages and microbial interactions
  • interferon and immune responses
  • Mosquito-borne diseases and control
  • Complement system in diseases
  • Inhalation and Respiratory Drug Delivery
  • Cell death mechanisms and regulation
  • Nanoplatforms for cancer theranostics
  • Autophagy in Disease and Therapy
  • RNA and protein synthesis mechanisms
  • Biochemical and biochemical processes
  • Neuroscience of respiration and sleep
  • Food Quality and Safety Studies

Institut Pasteur of Shanghai
2020-2022

Chang Gung University
2014-2019

National Chung Hsing University
2008-2013

Abstract Influenza is one of the most common human respiratory diseases, and represents a serious public health concern. However, high mutability influenza viruses has hampered vaccine development, resistant strains to existing anti-viral drugs have also emerged. Novel anti-influenza therapies are urgently needed, in this study, we describe properties Spirulina ( Arthrospira platensis ) cold water extract. Anti-viral effects previously been reported for extracts specific substances derived...

10.1038/srep24253 article EN cc-by Scientific Reports 2016-04-12

Abstract SARS-CoV-2, the causative agent of COVID-19 1 , features a receptor-binding domain (RBD) for binding to host cell ACE2 protein 1–6 . Neutralizing antibodies that block RBD-ACE2 interaction are candidates development targeted therapeutics 7–17 Llama-derived single-domain (nanobodies, ~15 kDa) offer advantages in bioavailability, amenability, and production storage owing their small sizes high stability. Here, we report rapid selection 99 synthetic nanobodies (sybodies) against RBD by...

10.1038/s41467-021-24905-z article EN cc-by Nature Communications 2021-07-30

ABSTRACT Avian influenza A viruses generally do not replicate efficiently in human cells, but substitution of glutamic acid (Glu, E) for lysine (Lys, K) at residue 627 avian virus polymerase basic protein 2 (PB2) can serve to overcome host restriction and facilitate infectivity. Although PB2 is regarded as a species-specific signature viruses, factors associated with E have yet be fully investigated. We conducted immunoprecipitation, followed by differential proteomic analysis, identify...

10.1128/mbio.00481-17 article EN cc-by mBio 2017-06-14

An avian influenza A H7N9 virus emerged in March 2013 and caused a remarkable number of human fatalities. Genome variability these viruses may provide insights into host adaptability. We scanned over 140 genomes the isolated from humans identified 104 positions that exhibited seven or more amino acid substitutions. Approximately half substitutions were ribonucleoprotein (RNP) complex. Although PB2 627K promotes replication humans, 45 147 investigated sequences retained E signature at this...

10.1371/journal.pone.0148432 article EN cc-by PLoS ONE 2016-02-04

Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, replicates primarily at the endoplasmic reticulum and thereby triggers apoptosis of infected cells. This study investigated hierarchical activation caspase network induced by JEV infection. It was found that activated initiators caspase-8 -9, as well effector caspase-3, in baby hamster kidney mouse neuroblastoma (N18) In neuronal N18 cells, infection triggered cytochrome c release from mitochondria, which turn caspase-9 -3....

10.1099/vir.0.2008/000182-0 article EN Journal of General Virology 2008-07-17

ABSTRACT SARS-CoV-2, the causative agent of COVID-19 1 , recognizes host cells by attaching its receptor-binding domain (RBD) to receptor ACE2 2–7 . Neutralizing antibodies that block RBD-ACE2 interaction have been a major focus for therapeutic development 8–18 Llama-derived single-domain (nanobodies, ∼15 kDa) offer advantages including ease production and possibility direct delivery lungs nebulization 19 which are attractive features bio-drugs against global respiratory disease. Here, we...

10.1101/2020.06.09.143438 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2020-06-10

The role of microRNA (miRNA) in influenza A virus (IAV) host species specificity is not well understood as yet. Here, we show that a miRNA, miR-1290, induced through the extracellular signal-regulated kinase (ERK) pathway upon IAV infection and associated with increased viral titers human cells ferret animal models. miR-1290 was observed to target reduce expression vimentin gene. Vimentin binds PB2 subunit ribonucleoprotein (vRNP), knockdown significantly vRNP nuclear retention polymerase...

10.1016/j.omtn.2019.04.028 article EN cc-by-nc-nd Molecular Therapy — Nucleic Acids 2019-05-15

Influenza B viruses are antigenically classified into Yamagata and Victoria lineages according to their hemagglutinin (HA) proteins. These two known either appear sequentially or cocirculate in Taiwan.Taiwanese influenza viral HA neuraminidase (NA) sequences between 2003 2014 were determined analyzed. A time-scaled phylogenetic tree was constructed decipher the evolutionary trends of these sequences, reassortment lineages. Positively selected amino acids predicted, demonstrating adaptive...

10.1016/j.jfma.2016.01.017 article EN cc-by-nc-nd Journal of the Formosan Medical Association 2016-04-01

Abstract SARS-CoV-2, the causative agent of COVID-19 1 , recognizes host cells by attaching its receptor-binding domain (RBD) to receptor ACE2 2-7 . Neutralizing antibodies that block RBD-ACE2 interaction have been a major focus for therapeutic development 8-18 Llama-derived single-domain (nanobodies, ~15 kDa) offer advantages including ease production and possibility direct delivery lungs nebulization 19 which are attractive features bio-drugs against global respiratory disease. Here, we...

10.21203/rs.3.rs-75540/v1 preprint EN cc-by Research Square (Research Square) 2020-09-23
Coming Soon ...